Registrieren

Registierung erfolgt in Kürze...
Fleebs-Logo
Details werden geladen...

Coty Announces Agreement With Kering for Early Transition of Gucci Beauty License

Coty to receive approximately $400 million in consideration for the early termination plus sale of sufficient Gucci Beauty inventory to support the transition Coty to continue operating Gucci

Ähnliche Seiten

https://www.manilatimes.net/2026/07/09/business/foreign-business/coty-exits-gucci-license-early/2381002

Coty exits Gucci license early | The Manila Times

https://www.manilatimes.net/2026/07/09/business/foreign-business/coty-exits-gucci-license-early/2381002
https://www.finanznachrichten.de/nachrichten-2026-07/68967142-l-oreal-l-oreal-enters-a-50-year-exclusive-worldwide-beauty-licence-with-kering-for-the-gucci-brand-399.htm

L'ORÉAL: L'Oréal enters a 50-year exclusive worldwide beauty licence with Kering for the Gucci brand

https://www.finanznachrichten.de/nachrichten-2026-07/68967142-l-oreal-l-oreal-enters-a-50-year-exclusive-worldwide-beauty-licence-with-kering-for-the-gucci-brand-399.htm
https://www.manilatimes.net/2026/06/30/tmt-newswire/globenewswire/vect-horus-announces-collaboration-and-license-option-agreement-with-servier-to-develop-targeted-oligonucleotide-therapeutics-for-rare-cns-diseases/2375405

Vect-Horus announces collaboration and license option agreement with Servier to develop targeted oligonucleotide therapeutics for rare CNS diseases | The Manila Times

https://www.manilatimes.net/2026/06/30/tmt-newswire/globenewswire/vect-horus-announces-collaboration-and-license-option-agreement-with-servier-to-develop-targeted-oligonucleotide-therapeutics-for-rare-cns-diseases/2375405
https://www.manilatimes.net/2026/07/06/tmt-newswire/globenewswire/astex-announces-exclusive-research-collaboration-and-license-agreement-with-genentech-for-breast-cancer-therapy-program/2378788

Astex Announces Exclusive Research Collaboration and License Agreement with Genentech for Breast Cancer Therapy Program | The Manila Times

https://www.manilatimes.net/2026/07/06/tmt-newswire/globenewswire/astex-announces-exclusive-research-collaboration-and-license-agreement-with-genentech-for-breast-cancer-therapy-program/2378788
https://www.manilatimes.net/2026/06/22/tmt-newswire/pr-newswire/antengene-announces-exclusive-license-agreement-with-mpm-bioimpact-established-k2-therapeutics-for-atg-106-and-option-for-undisclosed-bispecific-tce/2369714

Antengene Announces Exclusive License Agreement with MPM BioImpact-Established K2 Therapeutics for ATG-106 and Option for Undisclosed Bispecific TCE | The Manila Times

https://www.manilatimes.net/2026/06/22/tmt-newswire/pr-newswire/antengene-announces-exclusive-license-agreement-with-mpm-bioimpact-established-k2-therapeutics-for-atg-106-and-option-for-undisclosed-bispecific-tce/2369714
https://www.manilatimes.net/2026/05/18/tmt-newswire/globenewswire/context-therapeutics-enters-into-license-agreement-amendment-with-bioatla-for-ct-202/2346061

Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202 | The Manila Times

https://www.manilatimes.net/2026/05/18/tmt-newswire/globenewswire/context-therapeutics-enters-into-license-agreement-amendment-with-bioatla-for-ct-202/2346061